Copyright
©The Author(s) 2022.
World J Clin Cases. Jun 16, 2022; 10(17): 5667-5679
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5667
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5667
Table 1 Baseline and demographic characteristics of patients and cysts
| Characteristics | n = 98 | |
| Males (%) | 33 (33.7) | |
| Females (%) | 65 (66.3) | |
| Median age at diagnosis (IQR) | 69 (63-75) | |
| Familial history (%) | 9 (9.2) | |
| History of diabetes (%) | 16 (16.3) | |
| Diabetes onset during follow-up (%) | 0 (0.0) | |
| Median follow-up [mo (IQR)] | 40.5 (24-72) | |
| Former smokers (%) | 14 (14.3) | |
| Active smokers (%) | 8 (8.1) | |
| Never smoked (%) | 76 (77.6) | |
| Multifocal | 57 (58.2) | |
| Largest cyst localization | Head (%) | 44 (44.9) |
| Isthmus/body (%) | 40 (40.8) | |
| Tail (%) | 14 (14.3) | |
| Median cyst size | a [mm (IQR)] | 9 (6-15) |
| b [mm (IQR)] | 10 (6.75-16) | |
| c [mm (IQR)] | 10 (6-16) | |
| Volume [cm3 (IQR)] | 0.54 (0.17-1.65) | |
| EUS | 19 (19.4) | |
| Median time to EUS (IQR) | 6 (0-31.5) | |
| FNA (%) | 9 (47.4) | |
| Cyst fluid amylases [IU/L (IQR)], n = 5 | 289 (69.25-1725.25) | |
| Cyst fluid CEA [IU/L (IQR)], n = 6 | 166 (8.55-24062.75) | |
| Serum CA19.9 [IU/L (IQR)], n = 25 | 25.2 (6.1-58.7) | |
| Serum CEA [IU/L (IQR)], n = 22 | 2.15 (1.27-2.92) | |
Table 2 Baseline and demographic characteristics of patients and cysts: subgroups
| Non-worrisome features (n = 88) | Worrisome features (n = 10) | P value | ||
| Males (%) | 31 (35.2) | 2 (20.0) | 0.540234 | |
| Females (%) | 57 (64.8) | 8 (80.0) | 0.540234 | |
| Median age at diagnosis (IQR) | 70 (63.5-74.75) | 67 (59.75-76.25) | 0.58232 | |
| Familial history (%) | 8 (9.1) | 1 (10.0) | 0.628786 | |
| History of diabetes (%) | 14 (15.9) | 2 (20.0) | 0.904665 | |
| Diabetes onset during follow-up (%) | 0 (0.0) | 0 (0.0) | - | |
| Median follow-up [mo (IQR)] | 37.5 (23.25-71) | 69.5 (46.5-94) | 0.01828 | |
| Former smokers (%) | 11 (12.5) | 3 (30.0) | 0.306885 | |
| Active smokers (%) | 8 (9.1) | 0 (0.0) | 0.738111 | |
| Never smoked (%) | 69 (78.4) | 7 (70.0) | 0.83833 | |
| Multifocal | 52 (59.1) | 5 (50.0) | 0.830551 | |
| Largest cyst localization | Head (%) | 39 (44.3) | 5 (50.0) | 0.994538 |
| Isthmus/body (%) | 35 (39.8) | 5 (50.0) | 0.776364 | |
| Tail (%) | 14 (15.9) | 0 (0.0) | 0.746616 | |
| Median cyst size | a [mm (IQR)] | 9 (6-13) | 19 (11.25-21.25) | 0.0035 |
| b [mm (IQR)] | 10 (6-15) | 18 (10.75-20.75) | 0.00652 | |
| c [mm (IQR)] | 9.5 (6-15) | 22.5 (12-27.65) | 0.00424 | |
| EUS | 14 (15.9) | 5 (50.0) | 0.030618 | |
| Median time to EUS (IQR) | 3 (0-18.25) | 29 (5.5-69.5) | 0.22628 | |
| Serum CA19.9 [IU/L (IQR)], n = 25 | 6.2 (5.6-24.2) | 23.8 (6.2-37.9) | 0.1556 | |
| Serum CEA [IU/L (IQR)], n = 22 | 2.15 (1.28-2.93) | 2.15 (1.55-2.75) | 0.93624 | |
Table 3 Patients who underwent surgery
| Sex, age | Final cyst volume (cm3) | Growth rate (cm3/yr) | MPD (mm) | Location | CA19.9 (IU/L) | Time to surgery (mo) | Histopathology | |
| Patient A | F, 68 | 28.73 | 33.91 | < 5 | Isthmus | 33.2 | 85 | LGD |
| Patient B | F, 74 | 14.70 | 24.27 | < 5 | Head | 22.5 | 65 | LGD |
Table 4 Baseline cysts size
| All (n = 98) | Non-worrisome features (n = 88) | Worrisome features (n = 10) | P value | |
| a [mm (IQR)] | 9 (6-15) | 9 (6-13) | 19 (11.25-21.25) | 0.0035 |
| b [mm (IQR)] | 10 (6.75-16) | 10 (6-15) | 18 (10.75-20.75) | 0.00652 |
| c [mm (IQR)] | 10 (6-16) | 9.5 (6-15) | 22.5 (12-27.65) | 0.00424 |
| volume [cm3 (IQR)] | 0.54 (0.17-1.65) | 0.45 (0.15-1.28) | 5.28 (1.10-6.30) | 0.00222 |
Table 5 Final cysts size
| All (n = 98) | Non-worrisome features (n = 88) | Worrisome features (n = 10) | P value | |
| a [mm (IQR)] | 9 (6-16) | 9 (6-13.75) | 23 (13.5-27.5) | 0.00288 |
| b [mm (IQR)] | 12 (7-18) | 11 (7-16.75) | 28 (19.25-37.5) | 0.00054 |
| c [mm (IQR)] | 11 (7-18) | 10.5 (6.25-16) | 29 (15.75-38.75) | 0.0003 |
| volume [cm3 (IQR)] | 0.58 (1.76-2.02) | 0.52 (0.17-1.63) | 10.17 (2.72-19.36) | 0.0005 |
Table 6 Total cysts growth
| All (n = 98) | Non-worrisome features (n = 88) | Worrisome features (n = 10) | P value | |
| a [mm (IQR)] | 0 (-0.25-2) | 0 (-0.75-1.75) | 2 (-0.5-8.75) | 0.0601 |
| b [mm (IQR)] | 0 (0-3) | 0 (0-2) | 10 (-0.25-14.25) | 0.01016 |
| c [mm (IQR)] | 0 (0-3) | 0 (-1-2) | 5 (3.25-14) | 0.00008 |
| Volume [cm3 (IQR)] | 0.02 (-0.01-0.70) | 0 (-0.03-0.24) | 4.01 (0.83-13.87) | < 0.00001 |
| Volume increased (%) | 28 (28.6) | 18 (20.4) | 10 (100.0) | < 0.00001 |
| Volume unchanged or reduced (%) | 70 (71.4) | 70 (79.6) | 0 (0.0) | < 0.00001 |
Table 7 Yearly cysts growth rate
| All (n = 98) | Non-worrisome features (n = 88) | Worrisome features (n = 10) | P value | |
| a [mm/yr (IQR)] | 0 (-0.04-0.73) | 0 (-0.11-0.6) | 0.63 (-0.11-1.275) | 0.14156 |
| b [mm/yr (IQR)] | 0 (0-1.33) | 0 (0-1.09) | 1.55 (-0.53-3.52) | 0.0394 |
| c [mm/yr (IQR)] | 0 (0-0.99) | 0 (-0.29-0.71) | 1.96 (0.64-2.47) | 0.00152 |
| Volume [cm3/yr (IQR)] | 0 (-0.01-0.27) | 0 (-0.02-0.17) | 1.12 (0.28-2.65) | 0.0001 |
Table 8 First-year cysts growth and development of worrisome features
| All (n = 74) | Non-worrisome features (n = 64) | Worrisome features (n = 10) | P value | |
| a [mm (IQR)] | 0 (0-0.56) | 0 (0-0.5) | 0.47 (-0.11-1.1) | 0.22628 |
| b [mm (IQR)] | 0 (0-1.13) | 0 (0-0.14) | 0.4 (-1.12-2.81) | 0.64552 |
| c [mm (IQR)] | 0 (0-0.94) | 0 (0-0.74) | 1.4 (0-2.47) | 0.00932 |
| Volume [cm3 (IQR)] | 0 (-0.02-0.18) | 0 (-0.04-0.08) | 0.46 (0-1.62) | 0.00634 |
| Volume increased (%) | 35 (47.3) | 28 (43.7) | 7 (70.0) | 0.227942 |
| Volume unchanged or reduced (%) | 39 (52.7) | 36 (56.3) | 3 (30.0) | 0.227942 |
- Citation: Innocenti T, Danti G, Lynch EN, Dragoni G, Gottin M, Fedeli F, Palatresi D, Biagini MR, Milani S, Miele V, Galli A. Higher volume growth rate is associated with development of worrisome features in patients with branch duct-intraductal papillary mucinous neoplasms. World J Clin Cases 2022; 10(17): 5667-5679
- URL: https://www.wjgnet.com/2307-8960/full/v10/i17/5667.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i17.5667
